BeOne Medicines Ltd.
Close on Nov 2, 2026Market cap $41.08BP/E 64.6Yield –
BeOne Medicines REVLIMID (lenalidomide by Quarter
REVLIMID (lenalidomide — BMS/Celgene China Partnered) ($M, FY18–FY24) ($M)
BeOne Medicines REVLIMID (lenalidomide: $3.60M in Q4 2024, down 77.6% from a year earlier. That is the lowest of the 24 quarters on record here. No newer figure appears in the documents we track.
Where the Q4 2024 figure comes from
Calculated from reported figures: Q4 = full year (10-K) − nine months (10-Q)
Source: Form 10-K (filed 2025-02-27) ↗
Reported in Form 10-Q / 10-K Segment Disaggregation Note (XBRL).
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | REVLIMID (lenalidomide — BMS/Celgene China Partnered) ($M, FY18–FY24) ($M) | Year on year | Source |
|---|---|---|---|---|
| Q4 2024 | Dec 31, 2024 | 3.60 | -77.6% | Form 10-K (filed 2025-02-27) ↗ |
| Q3 2024 | Sep 30, 2024 | 11.1 | -26.0% | Form 10-Q (filed 2024-11-12) ↗ |
| Q2 2024 | Jun 30, 2024 | 9.10 | -58.4% | Form 10-Q (filed 2024-08-07) ↗ |
| Q1 2024 | Mar 31, 2024 | 12.2 | -47.4% | Form 10-Q (filed 2024-05-08) ↗ |
| Q4 2023 | Dec 31, 2023 | 16.1 | -12.5% | Form 10-K (filed 2025-02-27) ↗ |
| Q3 2023 | Sep 30, 2023 | 15 | -21.5% | Form 10-Q (filed 2024-11-12) ↗ |
| Q2 2023 | Jun 30, 2023 | 21.9 | +10.1% | Form 10-Q (filed 2024-08-07) ↗ |
| Q1 2023 | Mar 31, 2023 | 23.2 | +6.9% | Form 10-Q (filed 2024-05-08) ↗ |
| Q4 2022 | Dec 31, 2022 | 18.4 | -20.3% | Form 10-K (filed 2025-02-27) ↗ |
| Q3 2022 | Sep 30, 2022 | 19.1 | -5.4% | Form 10-Q (filed 2023-11-09) ↗ |
| Q2 2022 | Jun 30, 2022 | 19.9 | +95.1% | Form 10-Q (filed 2023-08-02) ↗ |
| Q1 2022 | Mar 31, 2022 | 21.7 | +30.7% | Form 10-Q (filed 2023-05-04) ↗ |
| Q4 2021 | Dec 31, 2021 | 23.1 | +171.8% | Form 10-K (filed 2024-02-26) ↗ |
| Q3 2021 | Sep 30, 2021 | 20.2 | +43.3% | Form 10-Q (filed 2022-11-09) ↗ |
| Q2 2021 | Jun 30, 2021 | 10.2 | -40.7% | Form 10-Q (filed 2022-08-08) ↗ |
| Q1 2021 | Mar 31, 2021 | 16.6 | +118.4% | Form 10-Q (filed 2022-05-09) ↗ |
| Q4 2020 | Dec 31, 2020 | 8.50 | -55.5% | Form 10-K (filed 2023-02-27) ↗ |
| Q3 2020 | Sep 30, 2020 | 14.1 | -25.8% | Form 10-Q (filed 2021-11-04) ↗ |
| Q2 2020 | Jun 30, 2020 | 17.2 | +4.9% | Form 10-Q (filed 2021-08-05) ↗ |
| Q1 2020 | Mar 31, 2020 | 7.60 | -67.8% | Form 10-Q (filed 2021-05-06) ↗ |
| Q4 2019 | Dec 31, 2019 | 19.1 | – | Form 10-K (filed 2022-02-28) ↗ |
| Q3 2019 | Sep 30, 2019 | 19 | – | Form 10-Q (filed 2020-11-05) ↗ |
| Q2 2019 | Jun 30, 2019 | 16.4 | – | Form 10-Q (filed 2020-08-06) ↗ |
| Q1 2019 | Mar 31, 2019 | 23.6 | – | Form 10-Q (filed 2020-05-11) ↗ |
Cite this data
StockData. (2026). BeOne Medicines REVLIMID (lenalidomide ($M), quarterly Q1 2019–Q4 2024 [Data set]. Compiled from BeOne Medicines SEC filings and investor materials. https://stockdatahq.com/stocks/onc/kpis/prod-revlimid
See every metric in the BeOne Medicines KPI table. Data updated Oct 29, 2026.